论文部分内容阅读
80年代以来经肝动脉化疗栓塞术 (ＴＡＣＥ)在肝癌围手术期的应用以及作为中晚期肝癌的首选治疗方法己取得了较好的近期疗效。但由于肝癌大多为肝动脉及门静脉双重供血 ,使单纯ＴＡＣＥ治疗后 3年 ,5年生存率仍不高〔1〕 。为进一步提高肿瘤局部的药物浓度 ,延长作用时间 ,更主
The application of transcatheter arterial chemoembolization (TACE) since the 1980s in the perioperative period of hepatocellular carcinoma and as the first choice of treatment for advanced hepatocellular carcinoma has achieved good short-term curative effect. However, due to liver cancer and portal vein are mostly double blood supply, so that after 3 years of pure TACE, 5-year survival rate is still not high 〔1〕. In order to further improve the local drug concentration in the tumor, prolong the duration of action, and more